Belarus Pharmaceuticals and Healthcare Industry Update Quarter 2 2012

Belarus Pharmaceuticals and Healthcare Industry Update Quarter 2 2012 Add to your bookmarks!

$ 1 088 - April 2013 - by Business Monitor International - 73

Summary

Table of Contents

View Report

Search Inside

Data Series

Industry

Drug and Medication

Country

Belarus

Keywords

Drug
Patented Drug
Medicine

Companies

Healthcare Insurance
Belbiopharm

Includes 3 FREE quarterly updates

BMI View: We expect the volatility in the performance of the Belarusian pharmaceutical market to
continue, with political tensions increasing risks to our forecasts Although the government aims to
increase local output and meet at least half of domestic drug demand, we note that currency devaluation
would have significantly increased the price of imported raw materials and manufacturing equipment At
the same time, the country’s political stance may potentially disrupt supplies of high-tech medicines
currently imported from a number of developed markets
Headline Expenditure Projections:
- Pharmaceuticals: BYR6,057bn in 2012 (US$725mn) to BYR7,574bn (US$872mn) in 2013;
+25 0% in local currency terms and +20 4% in US dollar terms Forecast upgraded slightly
from Q113 on the basis of new macroeconomic and trade data
- Healthcare: BYR26,431bn (US$3 16bn) in 2012 to BYR33,488bn (US$3 86bn) in 2013;
+26 7% in local currency terms and +22 0% in US dollar terms Forecast upgraded from Q113
on the basis of new macroeconomic data

Executive Summary 5
SWOT Analysis 7
Belarus Pharmaceuticals & Healthcare Industry SWOT 7
Belarus Political SWOT 8
Belarus Economic SWOT 8
Belarus Business Environment SWOT 9
Pharmaceutical Risk/Reward Ratings 10
Table: CEE Pharmaceutical Risk/Reward Ratings, Q213 10
Rewards 11
Risks 11
Belarus - Market Summary 13
Regulatory Regime 15
Recent Regulatory Developments 16
Pharmaceutical Advertising 16
Intellectual Property Rights 16
Counterfeit Drugs 17
Pricing And Reimbursement 18
Tendering Procedures 19
Industry Developments 20
Epidemiology 20
Healthcare Sector 21
Healthcare Provision 22
Healthcare Sector Reforms 22
Healthcare Insurance 23
Medical Tourism 23
Research And Development 23
Biotechnology 24
Clinical Trials 25
Industry Forecast Scenario 26
Pharmaceutical Market Forecast 26
Table: Belarus Pharmaceutical Sales, Historical Data and Forecasts, 2009-2017 28
Healthcare Market Forecast 29
Table: Belarus Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017 30
Table: Belarus Government Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017 30
Table: Belarus Private Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017 31
Key Growth Factors – Macroeconomic 32
Prescription Drug Market Forecast 36
Table: Belarus Prescription Drug Market Indicators, Historical Data and Forecasts, 2009-2017 37
Patented Drug Market Forecast 38
Table: Belarus Patented Drug Market Indicators, Historical Data and Forecasts, 2009-2017 39
Generic Drug Market Forecast 40
Table: Belarus Generics Drug Market Indicators, Historical Data and Forecasts, 2009-2017 41
OTC Medicine Market Forecast 42
Table: Belarus Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts, 2009-2017 44
Pharmaceutical Trade Forecast 45
Table: Belarus Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017 47
Table: Belarus Pharmaceutical Trade Data And Forecasts (BYRmn), 2009-2017 47
Other Healthcare Data 48
Key Risks To BMI’s Forecasts 49
Competitive Landscape 50
Pharmaceutical Sector 50
Domestic Drugmakers 51
Foreign Drugmakers 53
Recent Pharmaceutical Sector Developments 54
Pharmaceutical Wholesale And Retail 56
Company Profiles 57
Domestic Companies 57
Belbiopharm 57
Lekpharm 61
Demographic Outlook 63
Table: Belarus’ Population By Age Group, 1990-2020 (‘000) 64
Table: Belarus’ Population By Age Group, 1990-2020 (% of total) 64
Table: Belarus’ Key Population Ratios, 1990-2020 65
Table: Belarus’ Rural And Urban Population, 1990-2020 65
Glossary 67
BMI Methodology 69
How We Generate Our Pharmaceutical Industry Forecasts 69
Pharmaceuticals Risk/Reward Ratings Methodology 70
Ratings Overview 70
Table: Pharmaceutical Business Environment Indicators 71
Weighting 72
Table: Weighting Of Components 72

Drug and Medication in Belarus

Belarus Vaccine Exports, Us$mn, % Y-o-y

$ 250
Industry data
January 2013

Yearly, From 2003 To 2005
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

Industries : Drug and Medication
Countries : Belarus

Belarus Vaccine Exports, Byrmn

$ 250
Industry data
January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

Industries : Drug and Medication
Countries : Belarus

Belarus Vaccine Exports, Byrmn, % Y-o-y

$ 250
Industry data
January 2013

Yearly, From 2003 To 2005
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

Industries : Drug and Medication
Countries : Belarus

Belarus Vaccine Imports, Us$mn, % Y-o-y

$ 250
Industry data
January 2013

Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

Industries : Drug and Medication
Countries : Belarus

Belarus Vaccine Imports, Byrmn

$ 250
Industry data
January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

Industries : Drug and Medication
Countries : Belarus

Drug And Medication Industry in Belarus : Latest Reports

Vaccines - Global Markets Package

$ 24 060
Industry report
May 2013
by Global Research & Data Services

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market ...

Infertility Drugs And Devices Market - Global Industry Analysis, Size, Share And Forecast, 2010 - 2017

$ 4 395
Industry report
November 2013
by Transparency Market Research

This report is an effort to identify factors, which will be the driving force for the infertility drugs and devices market and sub-markets in the next few years. The report provides an extensive analysis ...

Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

$ 5 175
Industry report
March 2013
by Bioseeker

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three ...

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Angiogenesis A ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Breast Cancer, Angiogenes ...

March 2013 $ 5 175

Drug And Medication Industry in Belarus : Latest Downloads

Drug and Medication Industry Analysis

Industry report
April 2013
53 pages

... Use internally as part of a monthly cleansing regimen for gi health antibiotic, anti-inflammatory, antibacterial, antifungal, antioxidant, anti-parasitic, antiviral, disinfectant candida cleanse ...

Drug and Medication Market Brief

Industry report
April 2013
18 pages

... Antiosteoporosic drugs - casula m, filippi a, flacco e, gambera m, manzoli l, menditto e, orlando v, piccinelli r, tragni e, catapano a. Assessment and potential determinats of compliance and persistence to anti ...

Drug and Medication : Innovation and Technology Trends

Industry report
April 2013
12 pages

... Clinical regulatory toxicology phase i clinical phase ii clinical diabetes inflammation oncology (non-cytotoxic) anti-infectives clotting disorders obesity cns nce pipeline nce pipeline tyrosine-tzd, non ...